Rezdiffra (Resmetirom) Compounding Legal Status

What Is Rezdiffra and Why Was It Approved?

Rezdiffra (resmetirom) is the first drug the FDA has ever approved specifically for the treatment of MASH with liver fibrosis. On March 14, 2024, the agency granted it accelerated approval based on surrogate histological endpoints rather than long-term clinical outcomes like cirrhosis progression or liver transplant 1. This distinction matters for understanding both its clinical promise and its regulatory constraints.

Resmetirom works as a selective thyroid hormone receptor beta agonist. THR-β receptors are concentrated in the liver, and their activation drives hepatic fat metabolism, reduces lipotoxicity, and attenuates fibrogenesis 2. Unlike nonselective thyroid hormone analogs, resmetirom does not meaningfully activate THR-α, the receptor subtype responsible for cardiac and bone side effects. This selectivity allowed Madrigal Pharmaceuticals to develop a liver-targeted therapy without the tachycardia and osteoporosis risks that derailed earlier thyroid-based approaches.

The FDA's decision made Rezdiffra the only approved pharmacotherapy for a disease that affects an estimated 6 to 8 million Americans with the at-risk fibrotic phenotype 3. Before this approval, clinical management relied entirely on lifestyle modification, off-label use of pioglitazone or vitamin E, and treatment of comorbidities. No other drug had cleared the regulatory bar.

MAESTRO-NASH: The Key Trial Behind Approval

The phase 3 MAESTRO-NASH trial enrolled 966 adults with biopsy-confirmed MASH and fibrosis stage F1B, F2, or F3, randomizing them to resmetirom 80 mg, resmetirom 100 mg, or placebo for 52 weeks 2. The primary endpoints were MASH resolution with no worsening of fibrosis and fibrosis improvement by at least one stage with no worsening of the NAFLD Activity Score.

The results were clear. At week 52, MASH resolution without fibrosis worsening occurred in 25.9% of the 80 mg group and 29.9% of the 100 mg group, compared with 9.7% for placebo (P<0.001 for both comparisons) 2. Fibrosis improvement by at least one stage occurred in 24.2% (80 mg) and 25.9% (100 mg) versus 14.2% for placebo (P<0.001 and P=0.002, respectively).

Dr. Stephen Harrison, the trial's principal investigator and a hepatologist at Pinnacle Clinical Research, stated: "These data represent a turning point for patients with NASH. For the first time, we have a therapy that achieves both histologic resolution of steatohepatitis and improvement in fibrosis in a significant proportion of patients" 2.

LDL cholesterol also dropped by approximately 16% from baseline in resmetirom-treated patients, a secondary finding with potential cardiovascular relevance given the high cardiometabolic burden in the MASH population 2. Triglycerides fell as well. These lipid effects align with the known biology of hepatic THR-β activation.

Compounding Rezdiffra: The Legal Framework

Rezdiffra cannot be legally compounded under current federal law. The two main compounding pathways in the United States, Section 503A (patient-specific compounding by licensed pharmacies) and Section 503B (outsourcing facilities producing larger batches without patient-specific prescriptions), both prohibit compounding copies of commercially available drugs 4.

The legal test is straightforward. Under 503A, a pharmacy may compound a drug for an individual patient with a valid prescription, but the compounded product must not be "essentially a copy" of a commercially available drug unless that drug appears on the FDA's official shortage list 5. Rezdiffra is commercially available through Madrigal's distribution network. It does not appear on the FDA Drug Shortage Database. There is no approved generic. These three facts together close the 503A pathway for any standard compounded resmetirom product.

Section 503B outsourcing facilities face the same restriction with an even broader prohibition. They cannot compound drugs that are "essentially a copy of one or more approved drugs" regardless of patient-specific need unless the drug is on the shortage list or the compounder can demonstrate that the approved drug is not "therapeutically equivalent" to the compounded version in a clinically meaningful way 6.

A narrow exception exists. If a prescriber documents that a specific patient has a medical need for an altered formulation of resmetirom (for example, a liquid suspension for a patient who physically cannot swallow tablets), a 503A pharmacy could potentially prepare that specific formulation. But the compounded product must differ from the commercially available form in a clinically meaningful way. Simply replicating the 80 mg or 100 mg oral tablet at a lower cost would violate federal law.

Enforcement actions from the FDA against pharmacies compounding copies of branded drugs have increased since 2018. The agency issued warning letters to multiple compounding pharmacies producing copies of semaglutide injection, another drug not on the shortage list at the time of enforcement 7. The same legal principles apply to resmetirom.

What the Rezdiffra Label Specifies

The approved prescribing label for Rezdiffra defines a narrow indication: treatment of adults with noncirrhotic MASH with moderate to advanced hepatic fibrosis (consistent with stages F2 to F3), to be used in conjunction with diet and exercise 8. Several prescribing details are worth noting.

Dosing is weight-based. Patients weighing less than 100 kg receive 80 mg once daily. Patients at 100 kg or above receive 100 mg once daily. Both doses are taken orally with food. The label does not permit dose titration between the two strengths based on response; the weight threshold determines the dose 8.

Liver function monitoring is required. The label mandates baseline hepatic function testing (ALT, AST, total bilirubin, alkaline phosphatase) and repeat testing at months 3, 6, 9, and 12 during the first year of treatment. If ALT or AST rises above five times the upper limit of normal, resmetirom should be discontinued 8.

The label carries a specific limitation statement acknowledging accelerated approval: "This indication is approved under accelerated approval based on reduction in liver fat content. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s)" 8. The confirmatory study is MAESTRO-OUTCOMES, which is evaluating whether resmetirom reduces hard clinical endpoints including progression to cirrhosis, liver-related mortality, and major adverse cardiovascular events.

Dr. Mack Mitchell, a hepatologist at UT Southwestern Medical Center, has noted regarding the accelerated approval pathway: "Physicians need to understand that this approval rests on a surrogate marker, not on proven reduction of cirrhosis or death. The histology data are encouraging, but we are still waiting on the outcome trial to confirm durable clinical benefit" 9.

Safety Profile and Adverse Events

The safety data from MAESTRO-NASH showed a generally tolerable side effect profile, though gastrointestinal events were the most common treatment-emergent adverse effects. Diarrhea occurred in 27.5% of patients on resmetirom 100 mg versus 15.5% on placebo. Nausea affected 21.7% of the 100 mg group compared with 12.5% for placebo 2.

Most gastrointestinal symptoms were mild to moderate and tended to diminish after the first four to six weeks of treatment. Discontinuation due to adverse events occurred in 5.4% of the 80 mg group and 8.6% of the 100 mg group, versus 3.9% for placebo 2. These discontinuation rates are moderate by hepatology standards.

Thyroid-related safety was a key focus given the mechanism of action. TSH levels decreased modestly in resmetirom-treated patients, consistent with expected THR-β agonism, but clinical hypothyroidism was uncommon. Free T4 and free T3 levels remained within normal ranges in the majority of participants. No cases of thyrotoxicosis were reported 2.

Gallbladder-related events require attention. Cholelithiasis and cholecystitis occurred at numerically higher rates in the resmetirom groups (approximately 3.3% combined versus 1.7% placebo), although the differences did not reach statistical significance given the sample sizes 2. The prescribing label includes gallbladder events as a warning, and clinicians should counsel patients about symptoms of biliary disease 8.

Drug interactions listed on the label are limited but clinically relevant. Resmetirom may increase the effects of drugs metabolized by CYP2C8. Concomitant use with statins requires monitoring given that resmetirom itself reduces LDL cholesterol, and additive effects on hepatic transaminases could complicate safety monitoring 8. The label also notes that strong CYP3A4 inhibitors and CYP2C8 inhibitors have not been formally studied in combination with resmetirom.

Post-Market Surveillance and What Comes Next

The FDA's post-marketing requirements for Rezdiffra include completion of the MAESTRO-OUTCOMES trial, which enrolled approximately 5,000 patients with MASH and fibrosis stage F2 or F3 and is designed to detect reductions in liver-related clinical events and cardiovascular outcomes 10. Results are expected in 2028. If this trial fails to confirm clinical benefit, the FDA has the authority to withdraw the accelerated approval.

Real-world pharmacovigilance data collection is also ongoing. The FDA Sentinel system and the manufacturer's own post-marketing safety database will track for signals not detected in the controlled trial environment, particularly hepatotoxicity, gallbladder events, and thyroid function abnormalities at population scale 1.

For prescribers considering off-label use in patients with F1 or F4 fibrosis (compensated cirrhosis), neither subgroup was included in the key trial at sufficient numbers to support efficacy conclusions. The label explicitly limits the indication to noncirrhotic disease. Using resmetirom in patients with cirrhosis remains an open clinical question without supporting evidence.

Payer coverage continues to evolve. Madrigal Pharmaceuticals set the wholesale acquisition cost at approximately $47,400 per year. Prior authorization requirements vary by insurer, and most plans require biopsy-confirmed MASH with F2 or F3 fibrosis before approving coverage 11. Some insurers also require documented failure of lifestyle intervention.

How Rezdiffra Compares to Emerging MASH Therapies

Resmetirom does not exist in a therapeutic vacuum. Multiple MASH drug candidates are in late-stage clinical trials, and their regulatory trajectories may eventually change the compounding calculus for this disease class.

Semaglutide, already approved for type 2 diabetes and obesity, is being studied in MASH with the ESSENCE trial (NCT04822181). Obeticholic acid, a farnesoid X receptor agonist, received a Complete Response Letter from the FDA in 2020 despite positive fibrosis data in the REGENERATE trial, largely due to safety concerns including pruritus and LDL cholesterol increases 12. Lanifibranor, a pan-PPAR agonist, showed efficacy in the phase 2b NATiV3 trial and is advancing to phase 3 13.

None of these competitors have received FDA approval for MASH as of May 2026. Rezdiffra remains the only approved option. This commercial exclusivity, combined with active patent protection, reinforces the legal barriers against compounding. Even if another THR-β agonist were to reach the market, compounding pharmacies still could not produce resmetirom copies as long as the branded product remains available and off the shortage list.

The practical result for patients is that access to resmetirom runs through the branded supply chain: Madrigal's distribution network, specialty pharmacies, and the insurance prior authorization process. Clinicians seeking to prescribe this drug should familiarize themselves with Madrigal's patient assistance programs, which may offset costs for uninsured or underinsured patients with confirmed MASH and qualifying fibrosis stages.

Patients prescribed Rezdiffra should expect liver function testing at baseline and at months 3, 6, 9, and 12, with ongoing monitoring as clinically indicated thereafter 8.